Hey everyone, welcome back to ShareTreck! Today, we’re diving into a topic that has been requested by our community – Verve Therapeutics. It’s been a while since we checked in on them, so let’s see what’s happening in the world of Verve.
In this blog post, we’ll be discussing Verve’s pipeline, focusing on their lead candidate Verv 101 currently in Phase 1. We’ll touch on their cash balance and runway, and explore their collaborations with industry giants. So, let’s get started!
Pipeline Check:
First things first, let’s look at Verve’s pipeline. The gene therapy field often moves slowly due to the nature of research and clinical trials. Verve Therapeutics, however, seems to be progressing at a measured pace. Currently, only one therapy is in Phase 1, and monetization seems to be on the horizon, likely beyond this year and possibly into the next.
On a positive note, Verve has formed key alliances with industry heavyweights like Lily and Vertex. Notably, Eli Lilly has acquired commercialization rights for Verve 101 from Beam Therapeutics, which is a significant vote of confidence.
Financial Health:
Now, let’s talk about Verve’s financial health. In Q3 2023, R&D expenses increased by 24% compared to Q3 2022, indicating a healthy boost. While increased spending in research and development is expected, optimal execution is crucial for favorable outcomes.
G&A expenses also rose by 21.75%, but when we compare net loss per share for the same periods, there’s an improvement of 5 basis points. This suggests good fiscal control, with parameters moving in the right direction.
It’s worth highlighting that revenue for Verve will likely be erratic, depending on collaboration milestones being achieved. Timely milestone payments could be a source of revenue, demonstrating the importance of optimal execution.
Verve’s Prospects and Risks:
So, what’s the verdict on Verve Therapeutics? Firstly, their lead candidate, Verve 101, operates in a lucrative field. If approved, it has the potential to tap into a significant market, especially as they target Atherosclerotic Cardiovascular Disease (ASCVD).
However, this is a long-term play. Gains might take time, and investing early comes with inherent risks. Personal opinions aside, CRISPR Therapeutics seems to be catching more attention in the gene therapy arena.
Verve recently secured over $1.45 Million in funding, which is promising for avoiding immediate equity dilution. However, keep in mind that when they do monetize, they’ll have obligations to CRISPR Therapeutics and Editas for their licenses.
In conclusion, Verve Therapeutics is a long-term investment with risks, especially considering the uncertainties associated with clinical trials. What are your thoughts on Verve? Let us know in the comments below.
That’s it for now. Happy investing!
Sharetreck - Tracking Genomic Investments & clinical trials for HIV. 
Leave a comment